BeiGene celebrates profit milestone on soaring drug sales
Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis Key Takeaways: Global sales of the company’s…
No respite for RemeGen as problems and losses pile up
The developer of innovative drugs has sustained a series of blows to its finances, corporate partnerships, management team and star product, leaving investors jittery Key Takeaways: Despite rising revenue, RemeGen…
Junshi Biosciences Back in the Red, Pins Hopes on Covid Drugs
The innovative drug developer reported a first-quarter loss as a result of a steep drop in licensing revenue Key Takeaways: Junshi Biosciences’ revenue tumbled 61% in the first quarter, reflecting…
Recent Articles
BeiGene celebrates profit milestone on soaring drug sales
6160.HK
ONC.US
688325.SHG
No respite for RemeGen as problems and losses pile up
9995.HK
688331.SHG
RELATED ARTICLES
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- RNA drug developer Ribo Life targets fresh funding channel
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Innogen Pharma jostles for a slice of the weight-loss market
